Chin J Infect Dis , J une 2002 ,Vol 20 ,No . 3 Reverse Transcriptase Inhibitors , NN R TIs) 3 1995-2005 Tsinghua Tongfang Optical Disc Co., Ltd. All rights reserved. Chin J Infect Dis , J une 2002 ,Vol 20 ,No . 3 1995-2005 Tsinghua Tongfang Optical Disc Co., Ltd. All rights reserved. Chin J Infect Dis , J une 2002 ,Vol 20 ,No . 3 de Wolf F , Lange J M , Goudsmit J , et al. Effect of zidovudine on serum human immunodificiency virus antigen levels in symptom2 free subject s. Lancet , 1988 ,1 (8582) :3732376.
Concorde Coordinating committee. Concorde : MRC/ ANRS ran2 domized double2blind controlled trial of immediate and deferred zi2 dovudine in symptom2free HIV infection. Lancet , 1994 , 343 Fischl MA , Olson RM , Follansbee SE , et al. Zalcitabine com2 pared wit h zidovudine in patient s wit h advanced HIV21 infection who received previous zidovudine t herapy. Ann Intern Med , Alpha International Coordinating committee. The alpha t rial : Eu2 ropean/ Aust ralian randomized double2blind trial of two doses of didanosine in zidovudine2intolerant patients with symptomatic HV Pauwels R , Andries K , Desmyter D , et al. Potent and selective inhibitor of HIV21 replication in vitro by a novel series of TIBO derivatives. Nat ure , 1990 ,343 (6257) :4702474.
Nunberg J H , Schleif WA , Boot s EJ , et al. viral resistance to hu2 man immunodeficiency virus type 12specific pyridinone reverse t ranscriptase inhibitors. J Virol ,1991 ,65 :488724892.
Schooley R T , Ramirez2Ronda C , Lange J M , et al. Virologic and immunologic benefit s of initial combination t herapy wit h zidovu2 dine and zalcitabine or didanosine compared wit h zidovudine monot herapy. J Infect Dis ,1996 ,173 :135421366.
Markowitz M , Saag M , Powderly W G , et al. A preliminary st udy of ritonavir , an inhibitor of HIV21 protease , to treat HV21 infection. N Engl J Med , 1995 ,333 :153421539.
Masci J R. : outpatient management of HIV infection , CRC Press 1995-2005 Tsinghua Tongfang Optical Disc Co., Ltd. All rights reserved. Chin J Infect Dis , J une 2002 ,Vol 20 ,No . 3 Constantine N T. Quality assurance and standardization n clinical ity Mortalit y Weekly Report ,47 ( RR27) 1998 ,1233.
diagnostic immunological and molecular assays for human immun2 Onway B. Adherence and Directly Observed Therapy ( DO T) .
odeficiency. virus , in Nakancia RM , Burek Cl , Cook L , et al In : Internet Conference Report s , Dec. 16219 , 2001 , Chicago , ( eds :) Clinical diagnostic immunology2Blackweel Science Inc.
US Dept . of Healt h and Human Services : Guideline for t he use of Wei X , Ghosh S K , Taylor M E , et al. Viral dynamics in human antiret roviral agent s in HIV2infected adults and adolescents.
immunodeficiency virus type 1 infection. Nat ure , 1995 ,373 :1172 Wahington DC : US Dept . of Healt h and Human Services ; Lange J MA. and Montaner , J SG. : Anti2retroviral therapy and Roche and Trimeris Release : 48 week result s of two phase II resistance to anti2retroviral drug , In : Schuitemaker , H and st udies of Inhibitor T220 , at 9th Retrovirus Conference in Seattle ; Miedema , F. : AIDS pat hogenesis , Kluwer Academic Publish2 Rust schman O T , Opravil M , Iten A , et al. A placebo2controlled Carpenter CCJ , Fischl MA , Hammer SM , et al. Antiret roviral t rial of didanosine plus stavudine wit h and wit hout hydroxyurea t herapy for HIV infection in 1998 : updated recommendations of for HIV infection. AIDS , 1998 ,12 : F712F77.
t he International AIDS Society2USA Panel. J AMA , 1998 ,280 : Standst rom E , Wahren B , and Nordic VAC204 study Group : Therapeutic immunization wit h recombinant gp 160 in HIV21 in2 Karen M (ed) : HIV and AIDS2A global view , Greenwood Press , USA , 2002 , xii2xiii , 1832199 :2532271.
Notermans DW , J urriaans S , De Wolf , F , et al. Decrease of Kang L Y , Pan XZ , Yang WX , et al. Molecular st udies on effica2 HIV21 RNA levels in lymphoid tissue and peripheral blood during cy of Chinese herbal formula XQ29301 for AIDS treatment . XIII t reat ment wit h ritonavir , lamivudine and zidovudine. AIDS , International AIDS Conference Abst ract s : Volumn II , 2000 , P355 abst ract ThPeB5 192. Durban ,SA ,9214 J ul ,2000.
Sepkowitz KA. Effect of HAAR T on Nat ural history of AIDS2re2 L undgreu J D , HAAR T interruption increase risk of AIDS and lated opport unistic disorders. Lancet , 1998 ,351 :228.
deat h for most patient s , at t he 9th Conference on Ret roviruses and Zhang H , Dornadulo G , Beumont M , et al. Human immunodefi2 Opport unistic infections in Seattle , WA , February 24228 ,2002.
ciency virus type 1 in t he semen of men receiving highly active an2 Bolye B. www. hivandhepatitis. com/ recent/ haart/ 022202b.
tiret roviral t herapy. New Engl J Med , 1998 ,339 :180321809.
Landay AL , Bettendore D , Chan E , et al. Evidence of Immune Dirienzo A G , Vander Horst C , Finkelstein DM , et al. Efficacy Reconstit ution in Antiret roviral Drug2Experienced with advanced of Trimet hoprim2sulfamethoxazole for the prevention of bacterial HIV Disease. J . AIDS Research and Human Ret roviruses , 2002 , infections in a randomized prophylaxis t rial of patient s wit h ad2 vanced HIV infection. AIDS Research and Human Ret roviruses , Shatter N , Chuachoowang R , Mock PA , et al. Short2course zi2 dovudine for perinatal HIV21 transmissions in Bangkok , Thai2 Xu J Q , Whit man L , Lori F , et al. Met hods of using Interleukin land : a randomized cont rolled t rial. Lancet , 1999 ,333 :7732780.
2 to Enhance HIV2Specific Immune Response. AIDS Research Centers for Disease Cont rol and Prevention : Public Healt h Service and Human Ret roviruses ,2002 ,18 :2892293.
Guideline for t he management of healt h2care workers exposure to HIV and recommendations for post2exposure prophylaxis Morbid2 1995-2005 Tsinghua Tongfang Optical Disc Co., Ltd. All rights reserved.



Simulation Case Library: The Case of the Coiled Cardiac Catheter Kathleen R. Rosen, MD*; Elizabeth H. Sinz, MD** West Virginia University, Health Sciences Center, Morgantown, WV Original Article Abstract Many medical disciplines participate in the acute care ofhemodynamically unstable patients. At WVU we have manyopportunities for multidisciplinary critical care group instruction

Microsoft word - camperhealthcarerec.doc

CAMPER HEALTHCARE RECOMMENDATIONS BY LICENSED MEDICAL PERSONNEL FORM 2 To Parents(s)/Guardian(s): Complete this section and give this form (FORM 2) and a copy of your completed CAMPER HEALTH HISTORY FORM (FORM 1) to your child’s health-care provider for review. Camp Glen Brook Dates will attend camp: _____/_____/_____ to _____/_____/_____ 35 Glen Brook Rd. Month Day Year M

Copyright © 2010 Medicament Inoculation Pdf